Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growthin vivo

Tyrosinase Activated Melanoma Prodrugs

(2012) Samaila Jawaid et al.   Anti-Cancer Agents in Medicinal Chemistry

The association between Parkinson's disease and melanoma

(2011) Tianhong Pan et al.   INTERNATIONAL JOURNAL OF CANCER

High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease

(2011) R. Inzelberg et al.   JOURNAL OF NEURAL TRANSMISSION

Meta-analysis of the relationship between Parkinson disease and melanoma

(2011) R. Liu et al.   NEUROLOGY

Long-Term Efficacy of Rasagiline in Early Parkinson's Disease

(2010) Mark F. Lew et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Skin cancer and Parkinson's disease

(2010) Joaquim J. Ferreira et al.   MOVEMENT DISORDERS

Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

(2010) Orly Weinreb et al.   PROGRESS IN NEUROBIOLOGY

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

(2009) Orit Bar-Am et al.   JOURNAL OF NEUROCHEMISTRY

Reactive oxygen species: an Achilles’ heel of melanoma?

(2008) John P Fruehauf et al.   Expert Review of Anticancer Therapy